• News
  • BioTech

FDA grants Diazyme 510(k) clearance to market vitamin D assay

La Jolla's Diazyme Laboratories said that the U.S. Food and Drug Administration has granted 510(k) clearance to market its Vitamin D assay for Clinical Chemistry Analyzers.

In line with the increasing clinical demands for testing of this biomarker, Diazyme's new Vitamin D assay, utilizing its Femtoquant technology (a sensitive homogenous enzyme-immunoassay platform), provides the first fully automated Vitamin D test for use on general clinical chemistry analyzers. Diazyme's Vitamin D assay measures total 25-hydroxy Vitamin D (sum of 25-(OH)D3 + 25-(OH)D2) levels.

"Diazyme's Vitamin D assay is the first and the only Vitamin D test that is specifically designed for use on routine clinical chemistry analyzers. This innovative Vitamin D assay enables clinical laboratories of virtually all sizes to run Vitamin D test in house without the need for expensive specialized instruments. This high-throughput liquid stable assay provides precise test results, is user friendly, cost effective and has excellent correlation to the existing commercial methods. Diazyme's Vitamin D assay can help clinical laboratories improve their workflow and reduce their turnaround time for test results," said Dr. Chong Yuan, Managing Director of Diazyme Laboratories.

Diazyme Laboratories is a division of General Atomics.

User Response
0 UserComments

General Atomics

Company Website

P.O. 85608
San Diego, CA 92186

General Atomics Executive(s):

Neal Blue

  • Chairman, Chief Executive Officer

Linden Blue

  • Vice Chairman

Frank Pace

  • President, Aircraft Systems Group

Linden Blue

  • President, Reconnaissance Systems Group

Similar Companies

NAICS - 336411 - Aircraft Manufacturing
NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Other Lists